Transplantation of islets transduced with CTLA4-Ig and TGFβ using adenovirus and lentivirus vectors

被引:24
作者
Fernandes, JR
Duvivier-Kali, VF
Keegan, M
Hollister-Lock, J
Omer, A
Su, S
Bonner-Weir, S
Feng, S
Lee, JS
Mulligan, RC
Weir, GC
机构
[1] Harvard Univ, Sch Med, Sect Islet Transplantat & Cell Biol, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02215 USA
[3] Cominatorx Inc, Boston, MA 02118 USA
[4] Sanofi Synthelabo, Diabet & Obes Unit, Rueil Malmaison, France
[5] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA
关键词
diabetes; islet transplantation; adenovirus; lentivirus; cytotoxic T lymphocyte antigen 4; transforming growth factor beta;
D O I
10.1016/j.trim.2004.04.004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. A major problem facing islet transplantation is immune destruction of grafts by transplant rejection and autoimmunity. Some success in prolonging graft rejection has been obtained by transducing islets prior to transplantation with adenoviral (Ad) vectors containing CTLA4-Ig and TGFbeta. The purpose of this study was to see if lentiviral (LV) vectors would provide superior results compared with adenoviral vectors. Methods. Islets were isolated from Sprague-Dawley rats and transduced with Ad or LV vectors containing LacZ, CTLA4-Ig, TLA4, and TGFbeta1 using various MOIs. Islets transduced with LV were healthy as judged by DNA and insulin content, and insulin secretion. Using the kidney capsule transplant site, 500 transduced rat islets were transplanted into streptozotocin diabetic B6AF1 mice. Results. Maintenance of normoglycemia was prolonged in recipient mice carrying islets transduced with Ad vectors containing CTLA4-Ig, CTLA4, and TGFbeta1. Return of hyperglycemia in controls was 17-18 days while loss of function for the experimental groups occurred at 20-27 days. For the lentivirus transduced islets, rejection of controls was 20 +/- 1.6 days, for CTLA4-Ig was 42 21 days and for TGFbeta was 28 +/- 3.2 days. Conclusions. Although islets transduced with either adenovirus or lentivirus containing CTLA4-Ig, CTLA4, and TGFbeta1 could prolong graft survival in a rat to mouse transplantation model, with the conditions of this study lentivirus provided no advantage over adenovirus vectors. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:191 / 200
页数:10
相关论文
共 36 条
[1]   Co-stimulatory molecules in islet xenotransplantation: CTLA4Ig treatment in CD40 ligand-deficient mice [J].
Benda, B ;
Ljunggren, HG ;
Peach, R ;
Sandberg, JO ;
Korsgren, O .
CELL TRANSPLANTATION, 2002, 11 (07) :715-720
[2]  
Bright JJ, 1997, J IMMUNOL, V159, P175
[3]   TRANSFORMING GROWTH-FACTOR-BETA DECREASES THE IMMUNOGENICITY OF RAT ISLET XENOGRAFTS (RAT TO MOUSE) AND PREVENTS REJECTION IN ASSOCIATION WITH TREATMENT OF THE RECIPIENT WITH A MONOCLONAL-ANTIBODY TO INTERFERON-GAMMA [J].
CAREL, JC ;
SCHREIBER, RD ;
FALQUI, L ;
LACY, PE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (04) :1591-1595
[4]  
CHAHINE AA, 1995, TRANSPLANTATION, V59, P1313, DOI 10.1097/00007890-199505000-00016
[5]   Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis [J].
Chang, TT ;
Jabs, C ;
Sobel, RA ;
Kuchroo, VK ;
Sharpe, AH .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (05) :733-740
[6]   Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli [J].
Chartier, C ;
Degryse, E ;
Gantzer, M ;
Dieterle, A ;
Pavirani, A ;
Mehtali, M .
JOURNAL OF VIROLOGY, 1996, 70 (07) :4805-4810
[7]   Retroviral expression in embryonic stem cells and hematopoietic stem cells [J].
Cherry, SR ;
Biniszkiewicz, D ;
van Parijs, L ;
Baltimore, D ;
Jaenisch, R .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (20) :7419-7426
[8]   Prolonged xenograft survival of islets infected with small doses of adenovirus expressing CTLA4Ig [J].
Feng, S ;
Quickel, RR ;
Hollister-Lock, J ;
McLeod, M ;
Bonner-Weir, S ;
Mulligan, RC ;
Weir, GC .
TRANSPLANTATION, 1999, 67 (12) :1607-1613
[9]  
GAINER AL, ACTA DIABETOL, V34, P132
[10]   Targeting autoimmune diabetes with gene therapy [J].
Giannoukakis, N ;
Rudert, WA ;
Robbins, PD ;
Trucco, M .
DIABETES, 1999, 48 (11) :2107-2121